2014
Antimüllerian hormone as predictor of implantation and clinical pregnancy after assisted conception: a systematic review and meta-analysis
Tal R, Tal O, Seifer BJ, Seifer DB. Antimüllerian hormone as predictor of implantation and clinical pregnancy after assisted conception: a systematic review and meta-analysis. Fertility And Sterility 2014, 103: 119-130.e3. PMID: 25450298, DOI: 10.1016/j.fertnstert.2014.09.041.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Mullerian HormoneBiomarkersEmbryo ImplantationFemaleFertilization in VitroHumansInfertility, FemaleMiddle AgedObservational Studies as TopicOvarian ReserveOvaryOvulation InductionPregnancyPregnancy OutcomePregnancy RatePrevalenceReproducibility of ResultsRisk FactorsSensitivity and SpecificityYoung AdultConceptsPredictor of implantationClinical pregnancy rateAntimüllerian hormoneClinical pregnancyOvarian reservePregnancy rateOdds ratioIVF/intracytoplasmic sperm injectionSystematic reviewSerum AMH levelsPolycystic ovary syndromeReproductive technologiesIntracytoplasmic sperm injectionNondonor cyclesAMH levelsOvary syndromeImplantation rateDiagnostic odds ratioObservational studyMAIN OUTCOMEClinical utilitySperm injectionPregnancyAssisted conceptionFertility treatmentCharacterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes
Tal R, Seifer DB, Khanimov M, Malter HE, Grazi RV, Leader B. Characterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes. American Journal Of Obstetrics And Gynecology 2014, 211: 59.e1-59.e8. PMID: 24593938, DOI: 10.1016/j.ajog.2014.02.026.Peer-Reviewed Original ResearchConceptsSerum antimüllerian hormone levelsAntimüllerian hormone levelsClinical pregnancy ratePopulation of womenAMH levelsPregnancy rateHormone levelsHigher clinical pregnancy rateElevated AMH levelsPresence of amenorrheaMultiple pregnancy rateOvarian hyperstimulation syndromeRetrospective cohort studyHigher AMH levelsPolycystic ovarian morphologyPolycystic ovarian syndromeSyndrome phenotypeReproductive technology outcomesHyperstimulation syndromePCOS severityClinical pregnancyOvarian stimulationTotal testosteroneCohort studyOvarian syndrome
2013
Transforming growth factor-β1 and its receptor soluble endoglin are altered in polycystic ovary syndrome during controlled ovarian stimulation
Tal R, Seifer DB, Shohat-Tal A, Grazi RV, Malter HE. Transforming growth factor-β1 and its receptor soluble endoglin are altered in polycystic ovary syndrome during controlled ovarian stimulation. Fertility And Sterility 2013, 100: 538-543. PMID: 23684116, DOI: 10.1016/j.fertnstert.2013.04.022.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntigens, CDCase-Control StudiesEndoglinFemaleFertilization in VitroFollicular FluidHumansInfertility, FemaleOvarian Hyperstimulation SyndromeOvulation InductionPolycystic Ovary SyndromeReceptors, Cell SurfaceSperm Injections, IntracytoplasmicTransforming Growth Factor beta1UltrasonographyYoung AdultConceptsPolycystic ovarian syndromeSerum soluble endoglinDay of hCGSoluble endoglinFollicular fluidTGF-β1Oocyte retrievalOvarian stimulationHCG administrationControl womenDay 3Pathogenesis of PCOSNon-PCOS control groupProspective case-control studyNon-PCOS controlsSerum TGF-β1Non-PCOS womenPolycystic ovary syndromeTGF-β1 levelsReproductive technology unitCase-control studyGrowth factor-β1Day of retrievalOvarian hyperstimulationOvarian syndrome